Rapid Therapeutic Science Lab inc
Rapid Therapeutic Science Laboratories, Inc. focuses on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013… Read more
Rapid Therapeutic Science Lab inc (RTSL) - Total Liabilities
Latest total liabilities as of December 2024: $4.05 Million USD
Based on the latest financial reports, Rapid Therapeutic Science Lab inc (RTSL) has total liabilities worth $4.05 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rapid Therapeutic Science Lab inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Rapid Therapeutic Science Lab inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rapid Therapeutic Science Lab inc Competitors by Total Liabilities
The table below lists competitors of Rapid Therapeutic Science Lab inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AVINO SILVER & GOLD
MU:GV6
|
Germany | €21.48 Million |
|
YOC (YOC.SG)
STU:YOC
|
Germany | €10.91 Million |
|
Atos SE
PINK:AEXAF
|
USA | $7.27 Billion |
|
Soiltech ASA
OL:STECH
|
Norway | Nkr344.73 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Rapid Therapeutic Science Lab inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rapid Therapeutic Science Lab inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rapid Therapeutic Science Lab inc (2012–2024)
The table below shows the annual total liabilities of Rapid Therapeutic Science Lab inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.05 Million | -24.90% |
| 2022-12-31 | $5.40 Million | +50.66% |
| 2021-12-31 | $3.58 Million | +97.99% |
| 2019-12-31 | $1.81 Million | -37.38% |
| 2018-12-31 | $2.89 Million | 0.00% |
| 2018-03-31 | $2.89 Million | +9434.30% |
| 2017-12-31 | $30.30K | +168.69% |
| 2016-03-31 | $11.28K | 0.00% |
| 2015-12-31 | $11.28K | -148.96% |
| 2014-12-31 | $-23.03K | -45.15% |
| 2012-12-31 | $-41.99K | -- |